// App-Quantinova.ai

AB0500 (2021) : IMPACT OF COVID-19 PANDEMIC IN OVERALL HEALTH AND FUNCTIONING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE REUMAVID STUDY (PHASE 1)

Researchers

Presenter

  • D. Benavent

Principal Investigators

  • M. Garrido-Cumbrera

  • C. Plasencia

  • L. Christen

  • H. Marzo-Ortega

  • J. Correa-Fernndez

  • P. Plazuelo-Ramos

  • D. Webb

  • V. Navarro-Compn

Medical Centers

  • Hospital La Princesa, IIS-P, Rheumatology Department, Madrid, Spain

  • Universidad de Sevilla, Health & Territory Research (HTR), Seville, Spain

  • Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom

  • Novartis AG, Basel, Switzerland

  • University of Leeds, NIHR Leeds Biomedical Research Centre, LTHT and LIRMM, Leeds, United Kingdom

  • NCRI, London, United Kingdom

Locations

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Musculoskeletal

  • Infectious Diseases (ID)

Disease

  • Axial spondyloarthritis

  • Depression

  • Coronavirus disease

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • HI-6

Outcome

  • N/A

Study Design

  • Observational

  • Cross-Sectional

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved